Related Experiment Video

Updated: Oct 23, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Chemotherapy for mycosis fungoides and the Sézary syndrome

S T Rosen1, F M Foss

  • 1Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA.

Hematology/Oncology Clinics of North America
|October 1, 1995
PubMed

Insights

Conventional chemotherapy shows activity but not survival benefit in Mycosis Fungoides/Sézary Syndrome (MF/SS). Further research into agents like temozolomide and novel combinations is warranted for MF/SS patients.

Area of Science:

  • Oncology
  • Dermatology
  • Clinical Pharmacology

Background:

  • Mycosis Fungoides/Sézary Syndrome (MF/SS) are cutaneous T-cell lymphomas.
  • Conventional cytotoxic chemotherapy has shown activity in MF/SS but lacks clear survival benefit data.

Purpose of the Study:

  • To review the current landscape of chemotherapy for MF/SS.
  • To identify novel therapeutic agents and combinations for further clinical investigation.

Main Methods:

  • Literature review of cytotoxic chemotherapy agents in MF/SS.
  • Identification of emerging compounds and treatment strategies.

Main Results:

  • Conventional chemotherapy demonstrates anti-tumor activity but not improved survival in MF/SS.
  • Temozolomide, taxanes, and topoisomerase inhibitors (topotecan, CPT-11) are promising agents.
  • Combination of chemotherapy with biologic modalities remains unexplored.

Conclusions:

  • There is a need for novel therapeutic strategies in MF/SS.
  • Further clinical investigation of newer agents and combination therapies is crucial for improving patient outcomes in MF/SS.

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells08:50

Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells

Published on: June 26, 2026

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.